(Q40314887)

English

Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors

scientific article published on 18 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1 reference

based on heuristic

inferred from title

author name string

Christian Johannes Schmitt

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sascha Dietrich

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Antony Dick Ho

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Mathias Witzens-Harig

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

publication date

18 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

91

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

391-397

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Chemotherapy-induced acral erythema

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Recommendations for chamber quantification

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

A clinicopathologic analysis of adriamycin cardiotoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Cardiac safety of liposomal anthracyclines

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1308-Y

21 January 2018

Identifiers

10.1007/S00277-011-1308-Y

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40314887&oldid=1895019130"